DMT, oder N,N-Dimethyltryptamin, ist ein starkes Psychedelikum. DMT gehört wie seine psychedelischen Verwandten (LSD, MDMA, Psilocybin ... und sogar Marihuana) zu den kontrollierten Substanzen der Liste I. Der DEA zufolge ist das Missbrauchspotenzial hoch und es hat keinen medizinischen Nutzen. Außerdem, so die DEA, "geht die Geschichte der menschlichen Erfahrung wahrscheinlich zurück
Something strange happened yesterday. Psychedelics unicorn Compass Pathways released data for the largest clinical trial ever conducted of a psilocybin drug. Not only did the drug seem to work, but the heavily anticipated data were “breathtaking” in the words of Compass’ CEO. Immediately, the company’s publicly traded shares dropped 16%. Including the day prior, it
Das öffentliche und wissenschaftliche Interesse an Psychedelika wie Psilocybin und MDMA nimmt zu. Einst aufgrund des bundesstaatlichen Verbots verboten, hat sich ein Rinnsal von Forschungsarbeiten in den 1990er Jahren zu einem Strom entwickelt. Doch trotz zunehmender Akzeptanz in der Öffentlichkeit und kommerzieller Investitionen in psychedelische Therapien bremsen die alternden Bundesgesetze den Fluss der wichtigen Forschung. Psilocybin, ein
Excitement abounds about the status of MDMA, otherwise known as Ecstasy. And for good reason. As noted last month in the New York Times: …those who received MDMA during therapy [in clinical trials] experienced a significantly greater reduction in the severity of their symptoms compared with those who received therapy and an inactive placebo. Two
Bei Transaktionen mit Ketamin-Kliniken stellt sich häufig die Frage, ob eine Klinik oder ein Arzt (zusammenfassend als "Gesundheitsdienstleister" oder "Anbieter" bezeichnet) Ketamin für Off-Label-Anwendungen verwenden oder bewerben darf. Die kurze Antwort lautet: Ja, allerdings mit einigen Vorbehalten, die im Folgenden erläutert werden. Bevor die Antwort gegeben wird, ist es jedoch wichtig zu definieren, was "Off-Label"-Verwendung bedeutet und
Efforts by the Multidisciplinary Association for Psychedelic Studies (MAPS) to legalize prescription MDMA (Ecstasy) appear to have passed a gigantic hurdle earlier this month: MDMA is on track to meet the testing requirements to be a legalized prescription drug, specifically intended to treat the symptoms of post-traumatic stress disorder (PTSD). After analyzing the preliminary results
I was talking to another lawyer about last week’s vote by Oregonians to legalize psilocybin therapy here in the state. We discussed how licensed facilities won’t be up and running for a few more years, and how, in the meantime, people will have to make do with general decriminalization under Measure 109 and maybe, in
Last week, the Multidisciplinary Association for Psychedelics Studies (MAPS) made a very big announcement: it had raised $30 million to complete its promising study of MDMA (ecstasy; molly) for treating post-traumatic stress disorder (PTSD). The Food and Drug Administration (FDA) already has granted MAPS “breakthrough therapy” approval based on earlier trials. With its recent cash
Q: I want to study schedule I controlled substances. I want to study marijuana (cannabis), peyote, MDMA, psilocybin, LSD, ayahuasca/DMT and ibogaine, to start. A: All of that is possible, but you should choose just one. Q: OK, I want to study cannabis. A: That’s actually one of the hardest. Please choose a better one.
There is a bona fide movement underway with psilocybin. Decriminalization occurred last year in Denver, Oakland and Santa Cruz, and that was just a start: nearly 100 other cities are looking at decriminalizing psychedelics. At the state level, ballot measures are out for signature in California and Oregon. Federally, legislation has been proposed to allow
